Matthew Riese

Title: Matthew Riese: Innovator in T Cell Therapy

Introduction

Matthew Riese is a notable inventor based in Mequon, WI (US). He has made significant contributions to the field of immunotherapy, particularly in enhancing the efficacy of T cell treatments. With a total of 2 patents, Riese is at the forefront of innovative medical solutions.

Latest Patents

Riese's latest patents focus on the inhibition of diacylglycerol kinase (DGK) to augment adoptive T cell transfer. The inventions provide compositions and methods for inhibiting one or more DGK isoforms in a cell to enhance its cytolytic activity. In one embodiment, the cells may be modified to express a chimeric antigen receptor (CAR). This inhibition in T cells used for adoptive transfer increases their cytolytic activity, making it a promising approach for treating various conditions, including cancer, infections, and immune disorders.

Career Highlights

Matthew Riese is affiliated with the University of Pennsylvania, where he continues to advance research in the field of immunotherapy. His work is pivotal in developing new strategies for enhancing T cell function, which is crucial for effective cancer treatment.

Collaborations

Riese collaborates with esteemed colleagues such as Steven M Albelda and Liang-Chuan Wang. Their combined expertise contributes to the innovative research and development of T cell therapies.

Conclusion

Matthew Riese is a key figure in the advancement of T cell therapy, with his innovative patents paving the way for new treatment options. His work exemplifies the potential of scientific research to transform medical practices and improve patient outcomes.